Is biopharma’s Midas man Vivek Ramaswamy building a new IPO vehicle with Dermavant deal?
One of Vivek Ramaswamy’s fledgling, pre-IPO “vant” companies has swung another in-licensing deal to beef up its pipeline.
Dermavant Sciences, a subsidiary of Roivant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
